Radecka E, Magnusson M, Magnusson A
Department of Radiology, University Hospital of Uppsala, Sweden.
Acta Radiol. 2006 Apr;47(3):328-31. doi: 10.1080/02841850500492092.
To assess patient mortality and survival time, period of catheterization, and indications for percutaneous nephrostomy (PCN) withdrawal in patients treated with PCN for urinary obstruction due to malignancy.
A retrospective analysis of 151 patients treated with 257 PCNs in a 5-year period was performed. Data on survival time, duration of catheterization, and clinical end-points for PCN treatment were collected.
The median survival time of the patients was 255 days, while median catheterization time was 62 days. The majority of patients (84) died with the catheter. Indications for PCN withdrawal were surgery, stent treatment, catheter displacement, and response to medical treatment.
The majority of patients with malignancy treated with PCN have advanced disease and short life expectancy. Factors such as diagnosis, prognosis, economy, and the patient's preference influence the choice of urinary diversion method. However, PCN should be considered in patients with malignancy on grounds of safety and low cost.
评估因恶性肿瘤导致尿路梗阻而接受经皮肾造瘘术(PCN)治疗的患者的死亡率和生存时间、造瘘管留置时间以及拔除PCN的指征。
对5年内接受257次PCN治疗的151例患者进行回顾性分析。收集生存时间、造瘘管留置时间以及PCN治疗的临床终点数据。
患者的中位生存时间为255天,而中位造瘘管留置时间为62天。大多数患者(84例)在留置造瘘管期间死亡。拔除PCN的指征包括手术、支架治疗、造瘘管移位以及对药物治疗的反应。
大多数接受PCN治疗的恶性肿瘤患者病情已进展且预期寿命较短。诊断、预后、经济因素以及患者偏好等因素会影响尿路改道方法的选择。然而,基于安全性和低成本考虑,恶性肿瘤患者应考虑采用PCN。